ShockWave Medical, Inc
$13.1M 21,799 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. reported $12,749,404.11 across General Payments, Research, and Ownership to 8,264 physicians and teaching hospitals across 10,143 transactions.
- $12.7M
- All-tracks total
- 10,143
- Transactions
- 8,264
- Recipients
- −$416.1K
- General Payments vs PY2023
Apellis Pharmaceuticals, Inc. reported $12,749,404.11 across all CMS Open Payments tracks (General + Research + Ownership) to 8,264 physicians and teaching hospitals in Program Year 2024 - ranking #142 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $3,516,926.48, averaging $1.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer apellis-pharmaceuticals-inc Apellis Pharmaceuticals, Inc.
$12.7M · #142/1,925 · 0.1% industry · PY2024
- TOT $12.7M
- RANK #142
- SHARE 0.1%
- TXN 10,143
- RCP 8,264
- CAT 7
- GEN $3.5M
- ΔGEN −$416.1K
- TOP1 21.6%
- PY 2024
Volume peers
Nearest volume peer: ShockWave Medical, Inc ($13.1M)
Apellis Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Apellis Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $416.1K (−10.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: APELLIS PHARMACEUTICALS, INC.PY2023: APELLIS PHARMACEUTICALS, INC.PY2024: Apellis Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,932,976.85
- PY2024
- $3,516,926.48
What the Data Shows for Apellis Pharmaceuticals, Inc.
$12,749,404.11: that is what Apellis Pharmaceuticals, Inc. reported in payments to 8,264 physicians and teaching hospitals during Program Year 2024, spread across 10,143 transactions ($1.3K per transaction, $1.5K per recipient). The company sits at rank #142 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
449 transactions worth $1.5M make "Compensation for Services Other Than Consulting" the top general-payment category in the 7-category breakdown below, 42.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Apellis Pharmaceuticals, Inc. made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.5M, 42.5% of General Payments.
Apellis Pharmaceuticals, Inc. reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (42.5%), Consulting Fee (37.4%), and Food and Beverage (8.9%). The remaining 4 categories make up 11.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Apellis Pharmaceuticals, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $1.5M | 449 | 42.5% |
| Consulting Fee | $1.3M | 196 | 37.4% |
| Food and Beverage | $311.4K | 6,917 | 8.9% |
| Travel and Lodging | $207.7K | 469 | 5.9% |
| Honoraria | $141.4K | 62 | 4.0% |
| Space Rental or Facility Fees | $40.5K | 13 | 1.2% |
| Education | $4.3K | 158 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,147,353.02 (32.6%) of $3,516,926.48 in this company's General Payments records across 3,585 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Apellis Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Denver Health Medical Center
$758,112.59 across 12 reported transactions
- 2
Ehsan Rahimy
$121,682.29 across 64 reported transactions
- 3
Dilsher Dhoot
$97,282.41 across 57 reported transactions
- 4
Jonathan Jonisch
$97,199.77 across 67 reported transactions
- 5
Ankur Shah
$73,075.96 across 45 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Apellis Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Apellis Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Apellis Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Alcon Vision LLC
$13.4M 94,278 recipients
Compare payment profiles
EMD Serono, Inc.
$12.1M 34,007 recipients
Compare payment profiles
BeiGene USA, Inc.
$13.4M 11,760 recipients
Compare payment profiles
Ultradent Products Inc
$13.4M 17,574 recipients
Compare payment profiles
Blueprint Medicines Corporation
$13.5M 8,586 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.